Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
23.00
0.00 (0.00%)
At close: Dec 31, 2025, 4:00 PM EST
22.75
-0.25 (-1.09%)
Pre-market: Jan 2, 2026, 8:34 AM EST
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,294 employees as of December 31, 2024. The number of employees increased by 18 or 1.41% compared to the previous year.
Employees
1,294
Change (1Y)
18
Growth (1Y)
1.41%
Revenue / Employee
$487,325
Profits / Employee
-$448,090
Market Cap
2.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | 893 | 153 | 20.68% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RARE News
- 2 days ago - Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 2 days ago - Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 2 days ago - Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain - Benzinga
- 3 days ago - These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Market Watch
- 4 days ago - Ultragenyx's bone disease drug fails late-stage trials - Reuters
- 4 days ago - Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta - GlobeNewsWire
- 13 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings - Seeking Alpha